NanoMedicines Innovation Network

Nanomedicines, “smart” medicines that employ various forms of nanotechnology, are poised to have a revolutionary impact on drug development. Nanomedicines will deliver drugs, such as anticancer drugs, more specifically to sites of disease to dramatically improve efficacy and reduce toxicity, and will also enable gene therapies employing RNA and DNA that have the potential to treat most human diseases. Nanomedicines have enormous potential to become the dominant medicines of the future. The NanoMedicines Innovation Network (NMIN) is uniquely poised to reap this potential by building on the substantial achievements of Canadian scientists and entrepreneurs in nanomedicine. The NanoMedicines Innovation Network (NMIN) is advancing “smart” medicines to cure disease by delivering small molecule drugs more specifically to disease sites and enabling the clinical use of gene therapies. The nanomedicines field is a high-priority area for UBC in which it has a distinguished track record: UBC faculty have founded more than 10 nanomedicines spin-off companies leading to five nanomedicine products approved by the FDA and other regulatory agencies. The NanoMedicines Innovation Network (NMIN) is pleased to announce the 14 …. The NanoMedicines Innovation Network (NMIN) is pleased to introduce the 2023-24 ….